文献速递糖尿病

1型糖尿病患者有氧运动后无需调整德谷胰岛素剂量:ADREM研究

No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study.
PubMed 文献 · Diabetologia · 2023-03-07

ADREM研究为随机对照交叉试验,在18例低血糖风险较高的1型糖尿病成人中比较德谷胰岛素剂量减少40%、推迟并减少20%与不调整三种方案,受试者下午进行45分钟有氧运动。结果显示运动后夜间低血糖发生率在各方案间无差异,推迟给药增加高血糖时间,数据不支持单次运动后调整德谷胰岛素剂量。

要点

  • 运动后夜间低血糖发生率在德谷胰岛素不减量、减量40%与推迟并减量20%三方案间无差异。
  • 次日全天低血糖时间减量40%组低于不调整组,但低血糖事件数无差异。
  • 推迟并减量20%组高血糖时间高于不调整组和减量40%组,应避免推迟给药。

核心结论

  • 运动后调整德谷胰岛素剂量不能降低1型糖尿病患者随后夜间低血糖风险。
  • 减量虽减少次日低血糖时间,但未减少低血糖事件数;推迟给药因增加高血糖时间应避免。
  • 数据不支持单次运动后调整德谷胰岛素剂量。

研究设计与样本

  • ADREM研究为随机对照交叉试验,纳入18例低血糖风险较高的1型糖尿病成人,女性6例,年龄38±13岁,HbA1c 56±8 mmol/mol(7.3±0.8%),均值±标准差。
  • 受试者下午进行45分钟有氧运动测试,比较德谷胰岛素减量40%(D40)、推迟并减量20%(D20-P)与不调整(CON)三种方案。
  • 所有参与者佩戴盲法连续葡萄糖监测6天,评估低血糖(夜间)发生率及后续血糖谱。

主要发现

  • 运动测试后夜间血糖低于3.9 mmol/l的时间总体较低,各治疗方案间发生率无差异。
  • 随后全天血糖低于3.9 mmol/l的时间D40组低于CON组(中位数[四分位距],0[0-23] vs 18[0-55]分钟,p=0.043),低血糖事件数无差异。
  • 血糖高于10 mmol/l的时间D20-P组高于CON组(均值±标准误,584±81 vs 364±66分钟,p=0.001)及D40组(385±72分钟,p=0.003)。

临床怎么用

  • 原文结论认为运动后调整德谷胰岛素剂量不能降低夜间低血糖风险,且推迟给药因增加高血糖时间应避免,数据不支持单次运动后调整剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: It is generally recommended to reduce basal insulin doses after exercise to reduce the risk of post-exercise nocturnal hypoglycaemia. Based on its long t½, it is unknown whether such adjustments are required or beneficial for insulin degludec. METHODS: The ADREM study (Adjustment of insulin Degludec to Reduce post-Exercise (nocturnal) hypoglycaeMia in people with diabetes) was a randomised controlled, crossover study in which we compared 40% dose reduction (D40), or postponement and 20% dose reduction (D20-P), with no dose adjustment (CON) in adults with type 1 diabetes at elevated risk of hypoglycaemia, who performed a 45 min aerobic exercise test in the afternoon. All participants wore blinded continuous glucose monitors for 6 days, measuring the incidence of (nocturnal) hypoglycaemia and subsequent glucose profiles. RESULTS: We recruited 18 participants (six women, age 38 ± 13 years, HbA1c 56 ± 8 mmol/mol [7.3 ± 0.8%], mean ± SD). Time below range (i.e. glucose <3.9 mmol/l) the night after the exercise test was generally low and occurrence did not differ between the treatment regimens. During the subsequent whole day, time below range was lower for D40 compared with CON (median [IQR], 0 [0-23] vs 18 [0-55] min, p=0.043), without differences in the number of hypoglycaemic events. Time above range (i.e. glucose >10 mmol/l) was greater for D20-P vs CON (mean ± SEM, 584 ± 81 vs 364 ± 66 min, p=0.001) and D40 (385 ± 72 min, p=0.003). CONCLUSIONS/INTERPRETATION: Post-exercise adjustment of degludec does not mitigate the risk of subsequent nocturnal hypoglycaemia in people with type 1 diabetes. Although reducing degludec reduced next-day time below range, this did not translate into fewer hypoglycaemic events, while postponing degludec should be avoided because of increased time above range. Altogether, these data do not support degludec dose adjustment after a single exercise bout. TRIAL REGISTRATION: EudraCT number 2019-004222-22 FUNDING: The study was funded by an unrestricted grant from Novo Nordisk, Denmark.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Drenthen LCA, Ajie M, Abbink EJ, et al. No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study. Diabetologia. 2023. PMID: 36879098. doi:10.1007/s00125-023-05893-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。